Bosnian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
phenylketonurias/dijareja
Veza se sprema u međuspremnik
4 rezultati
Treatment of phenylketonuria with a formula consisting of low-phenylalanine peptide. A collaborative study.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
A method of preparation of a more palatable therapeutic formula for phenylketonuria (PKU), consisting of low-phenylalanine peptide (LPP), was reported. There were no adverse effects and, in fact, there was a reduced frequency of diarrhea in patients who received LPP formula for more than 6 months.
Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND
Phenylketonuria (PKU) results from impaired breakdown of phenylalanine (Phe) due to deficient phenylalanine hydroxylase (PAH) activity. Sapropterin dihydrochloride (sapropterin, Kuvan®) is the only US- and EU-approved pharmaceutical version of naturally occurring 6R-BH(4), the cofactor
Man made disease: clinical manifestations of low phenylalanine levels in an inadequately treated phenylketonuria patient and mouse study.
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
BACKGROUND
Phenylalanine (Phe) deficiency and its clinical manifestations have been previously described mostly as sporadic case reports dating back to the 1960's and 1970's. In these reports, low plasma Phe levels were associated with listlessness, eczematous eruptions and failure to gain weight,
[Efficacy and safety of a phenylalanine-free amino acid-based enteral formula (AA-PKU2) in 1-8 year-old children with phenylketonuria: a prospective, open, self-controlled and multi-center study in China].
Samo registrirani korisnici mogu prevoditi članke
Prijavite se / prijavite se
OBJECTIVE
To evaluate the efficacy and safety of a phenylalanine-free amino acid-based enteral formula (AA-PKU2) in the treatment of children with phenylketonuria (PKU) aged 1-8 years.
METHODS
A prospective, open, self-controlled, multi-center trial was performed, enrolling 121 PKU children (1-8
Najkompletnija baza ljekovitog bilja potpomognuta naukom
- Radi na 55 jezika
- Biljni lijekovi potpomognuti naukom
- Prepoznavanje biljaka po slici
- Interaktivna GPS karta - označite bilje na lokaciji (uskoro)
- Pročitajte naučne publikacije povezane sa vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoja interesovanja i budite u toku sa istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Sve informacije temelje se na objavljenim naučnim istraživanjima
